Redmile Group, LLC - 14 Aug 2025 Form 4 Insider Report for IGM Biosciences, Inc. (IGMS)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: IGMS
Reported as of: 14 Aug 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Aug 2025, 17:00:13 UTC
Prior SEC filing: 16 Jul 2025
Next SEC filing: 26 Aug 2025
Source filing: View source filing
Reporting owner signature: By: /s/ Jeremy Green, Managing Member of Redmile Group, LLC

Key filing fact

Redmile Group, LLC filed Form 4 for IGM Biosciences, Inc. (IGMS) on 15 Aug 2025.

Key facts

This page summarizes Redmile Group, LLC's Form 4 filing for IGM Biosciences, Inc. (IGMS).
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 15 Aug 2025, 17:00.

Change

Previous filing in this sequence was filed on 16 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (2)

CIK 0001425738 Primary reporting owner

Redmile Group, LLC

Relationship: Director, 10%+ Owner
Address: ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO
Signature: By: /s/ Jeremy Green, Managing Member of Redmile Group, LLC
Signature date: 15 Aug 2025

CIK 0001650527

Green Jeremy

Relationship: 10%+ Owner
Address: C/O REDMILE GROUP, LLC (NY OFFICE), 45 W. 27TH STREET, FLOOR 11, NEW YORK
Signature: /s/ Jeremy Green
Signature date: 15 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IGMS transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -2,964,843
Change %: -100%
Price
Shares after: 0
Date: 14 Aug 2025
Ownership: See Footnotes
Footnotes: F1, F5, F6

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IGMS transaction Derivative

Non-Voting Common Stock

Disposed to Issuer

Transaction value
Shares: -7,199,325
Change %: -100%
Price
Shares after: 0
Date: 14 Aug 2025
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 7,199,325
Exercise price
Footnotes: F1, F3, F5, F6

IGMS transaction Derivative

Pre-Funded Warrants to Purchase Common Stock

Disposed to Issuer

Transaction value
Shares: -667,666
Change %: -100%
Price
Shares after: 0
Date: 14 Aug 2025
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 667,666
Exercise price: $0.0100
Footnotes: F2, F4, F5, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Redmile Group, LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 6 footnotes

Footnote F1

On August 14, 2025, pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 1, 2025, among the Issuer, Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer to purchase all outstanding shares of the Issuer's Common Stock and Non-Voting Common Stock ("Issuer Shares") in exchange for (a) a price per share of $1.247 in cash (the "Offer Price"), subject to applicable tax withholding and without interest, plus (b) one contingent value right ("CVR") per share subject to the terms and conditions of a Contingent Value Rights Agreement ("CVR Agreement"). The tender offer expired one minute following 11:59 p.m., Eastern Time, on August 13, 2025 (the "Offer Closing").

Footnote F2

On August 14, 2025, the Issuer completed its merger transaction with and into Merger Sub pursuant to the terms of the Merger Agreement, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). At the effective date and time of the Merger (the "Merger Closing"), each outstanding and unexercised pre-funded warrant to purchase shares of the Issuer's Common Stock (each, a "Pre-Funded Warrant") was cancelled and the holder received the right to a cash amount based on the Offer Price, subject to applicable tax withholding and without interest, less the exercise price per share underlying the Pre-Funded Warrant, plus one CVR per underlying share subject to the terms and conditions of a CVR Agreement.

Footnote F3

The Non-Voting Common Stock was convertible into shares of the Issuer's common stock at any time, in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time and from time to time at the holder's election on a 1-for-1 basis. The Non-Voting Common Stock had no expiration date.

Footnote F4

The Pre-Funded Warrants to purchase common stock of the Issuer have no expiration date.

Footnote F5

The Common Stock, Non-Voting Common Stock, and Pre-Funded Warrants of the Issuer reported herein were directly owned by certain private investment vehicles managed by Redmile (each, a "Redmile Fund"), and may have been deemed beneficially owned by Redmile as investment manager of the Redmile Funds.

Footnote F6

The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile (collectively with Redmile, the "Reporting Persons"). The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, if any, and this Form 4 shall not be deemed an admission that either Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC remarks

Michael Lee, a managing director of Redmile, resigned as a member of the board of directors of the Issuer immediately prior to the Merger Closing.